FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137803439> ?p ?o ?g. }

• W2137803439 endingPage "2037" @default.
• W2137803439 startingPage "2030" @default.
• W2137803439 abstract "ABSTRACT U.S. Food and Drug Administration draft guidance for future antibiotic clinical trials of bacterial nosocomial pneumonia recommends the use of diagnostic criteria according to American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines and the use of a primary endpoint of 28-day all-cause mortality. The effect of applying these guidelines on outcomes of phase III nosocomial pneumonia studies of telavancin was evaluated in a post hoc analysis. ATS/IDSA criteria were applied in a blind fashion to the original all-treated (AT) group. Clinical cure rates at final follow-up were determined in the refined AT and clinically evaluable (CE) groups (ATS/IDSA-AT and ATS/IDSA-CE, respectively). The exploratory endpoint of 28-day survival was evaluated for the ATS/IDSA-AT group. Noninferiority of telavancin versus vancomycin was demonstrated, with similar cure rates in the ATS/IDSA-AT (59% versus 59%) and ATS/IDSA-CE (83% versus 80%) groups. Cure rates favored telavancin in ATS/IDSA-CE patients where Staphylococcus aureus was the sole pathogen (86% versus 75%). Overall, 28-day survival rates were similar in the telavancin (76%) and vancomycin (77%) groups but lower in telavancin-treated patients with preexisting moderate-to-severe renal impairment (creatinine clearance [CL CR ] of <50 ml/min). Telavancin should be administered to patients with moderate-to-severe renal impairment only if treatment benefit outweighs the risk or if no suitable alternatives are available." @default.
• W2137803439 created "2016-06-24" @default.
• W2137803439 creator A5010409085 @default.
• W2137803439 creator A5011326404 @default.
• W2137803439 creator A5019419595 @default.
• W2137803439 creator A5020757594 @default.
• W2137803439 creator A5026604447 @default.
• W2137803439 creator A5059959498 @default.
• W2137803439 creator A5061401429 @default.
• W2137803439 date "2014-04-01" @default.
• W2137803439 modified "2023-09-28" @default.
• W2137803439 title "Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival" @default.
• W2137803439 cites W1761182137 @default.
• W2137803439 cites W1969798675 @default.
• W2137803439 cites W1970492397 @default.
• W2137803439 cites W2000673760 @default.
• W2137803439 cites W2043132544 @default.
• W2137803439 cites W2112604687 @default.
• W2137803439 cites W2121833044 @default.
• W2137803439 cites W2123175723 @default.
• W2137803439 cites W2126915534 @default.
• W2137803439 cites W2128076923 @default.
• W2137803439 cites W2129197867 @default.
• W2137803439 cites W2142827309 @default.
• W2137803439 cites W2152344036 @default.
• W2137803439 cites W4211194064 @default.
• W2137803439 doi "https://doi.org/10.1128/aac.02330-13" @default.
• W2137803439 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4068494" @default.
• W2137803439 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24419353" @default.
• W2137803439 hasPublicationYear "2014" @default.
• W2137803439 type Work @default.
• W2137803439 sameAs 2137803439 @default.
• W2137803439 citedByCount "53" @default.
• W2137803439 countsByYear W21378034392014 @default.
• W2137803439 countsByYear W21378034392015 @default.
• W2137803439 countsByYear W21378034392016 @default.
• W2137803439 countsByYear W21378034392017 @default.
• W2137803439 countsByYear W21378034392018 @default.
• W2137803439 countsByYear W21378034392019 @default.
• W2137803439 countsByYear W21378034392020 @default.
• W2137803439 countsByYear W21378034392021 @default.
• W2137803439 countsByYear W21378034392022 @default.
• W2137803439 countsByYear W21378034392023 @default.
• W2137803439 crossrefType "journal-article" @default.
• W2137803439 hasAuthorship W2137803439A5010409085 @default.
• W2137803439 hasAuthorship W2137803439A5011326404 @default.
• W2137803439 hasAuthorship W2137803439A5019419595 @default.
• W2137803439 hasAuthorship W2137803439A5020757594 @default.
• W2137803439 hasAuthorship W2137803439A5026604447 @default.
• W2137803439 hasAuthorship W2137803439A5059959498 @default.
• W2137803439 hasAuthorship W2137803439A5061401429 @default.
• W2137803439 hasBestOaLocation W21378034391 @default.
• W2137803439 hasConcept C126322002 @default.
• W2137803439 hasConcept C141071460 @default.
• W2137803439 hasConcept C159641895 @default.
• W2137803439 hasConcept C177713679 @default.
• W2137803439 hasConcept C203092338 @default.
• W2137803439 hasConcept C2777914695 @default.
• W2137803439 hasConcept C2778980435 @default.
• W2137803439 hasConcept C2779489039 @default.
• W2137803439 hasConcept C501593827 @default.
• W2137803439 hasConcept C523546767 @default.
• W2137803439 hasConcept C535046627 @default.
• W2137803439 hasConcept C54355233 @default.
• W2137803439 hasConcept C67761136 @default.
• W2137803439 hasConcept C71924100 @default.
• W2137803439 hasConcept C86803240 @default.
• W2137803439 hasConcept C89423630 @default.
• W2137803439 hasConceptScore W2137803439C126322002 @default.
• W2137803439 hasConceptScore W2137803439C141071460 @default.
• W2137803439 hasConceptScore W2137803439C159641895 @default.
• W2137803439 hasConceptScore W2137803439C177713679 @default.
• W2137803439 hasConceptScore W2137803439C203092338 @default.
• W2137803439 hasConceptScore W2137803439C2777914695 @default.
• W2137803439 hasConceptScore W2137803439C2778980435 @default.
• W2137803439 hasConceptScore W2137803439C2779489039 @default.
• W2137803439 hasConceptScore W2137803439C501593827 @default.
• W2137803439 hasConceptScore W2137803439C523546767 @default.
• W2137803439 hasConceptScore W2137803439C535046627 @default.
• W2137803439 hasConceptScore W2137803439C54355233 @default.
• W2137803439 hasConceptScore W2137803439C67761136 @default.
• W2137803439 hasConceptScore W2137803439C71924100 @default.
• W2137803439 hasConceptScore W2137803439C86803240 @default.
• W2137803439 hasConceptScore W2137803439C89423630 @default.
• W2137803439 hasIssue "4" @default.
• W2137803439 hasLocation W21378034391 @default.
• W2137803439 hasLocation W21378034392 @default.
• W2137803439 hasLocation W21378034393 @default.
• W2137803439 hasLocation W21378034394 @default.
• W2137803439 hasLocation W21378034395 @default.
• W2137803439 hasOpenAccess W2137803439 @default.
• W2137803439 hasPrimaryLocation W21378034391 @default.
• W2137803439 hasRelatedWork W1769504474 @default.
• W2137803439 hasRelatedWork W2047967234 @default.
• W2137803439 hasRelatedWork W2092505418 @default.
• W2137803439 hasRelatedWork W2162788500 @default.
• W2137803439 hasRelatedWork W2247376599 @default.
• W2137803439 hasRelatedWork W2409546295 @default.

• next